Creatine Supplements May Provide New Hope for Depression Treatment

Recent research suggests that creatine monohydrate, a popular supplement often used by athletes to enhance muscle performance, might also offer benefits for individuals suffering from major depressive disorder (MDD). A systematic review conducted by researchers from the University of Ottawa and the University of Toronto explored the potential of creatine as an adjunct treatment for this mental health condition, revealing promising yet mixed results.

The review, published in the journal *Brain Medicine*, analyzed various randomized controlled trials (RCTs) from around the globe. It highlighted that creatine supplementation may help alleviate symptoms of depression, particularly in those who do not respond adequately to conventional treatments. With approximately 332 million individuals affected by depression worldwide, the need for additional therapeutic options is increasingly urgent.

Researchers identified creatine’s role in cellular energy metabolism as a potential factor in its effectiveness against depression. They noted that compromised energy metabolism and mitochondrial dysfunction are often linked to depressive disorders. By acting as an energy buffer for brain cells, creatine might help restore normal cellular functions that are disrupted in individuals experiencing depression.

The systematic review assessed five RCTs involving 238 participants, with doses of creatine ranging from 2 to 10 grams per day over treatment periods of four to eight weeks. Some studies examined the impact of creatine in conjunction with antidepressants, while others evaluated its effects alongside cognitive behavioral therapy (CBT). Standard clinical scales, such as the Hamilton Depression Rating Scale, were used to measure changes in depressive symptoms.

Despite the promising potential of creatine, the review yielded mixed results. Some trials indicated significant improvements in depressive symptoms, particularly among women taking 5 grams of creatine daily alongside the antidepressant escitalopram. Others, however, found little to no benefit, including a study where participants with treatment-resistant depression did not experience symptom relief after four weeks of supplementation.

While creatine was generally well tolerated, with only mild digestive side effects reported, the majority of study participants were women, and the overall sample sizes were small. This raises questions about the applicability of the findings to a broader population. Moreover, animal studies suggest that the effects of creatine may differ between genders, which could explain the varying results across trials.

Experts emphasize that, while creatine shows promise as an adjunctive therapy for MDD, it should not replace existing treatment plans. Patients considering creatine supplementation are advised to consult their healthcare providers, especially if they have underlying health issues or are taking other medications.

In addition to exploring new treatments, maintaining a comprehensive approach to mental health is crucial. Lifestyle factors such as regular exercise, quality sleep, balanced nutrition, and effective stress management play essential roles in supporting brain health. As research continues, larger and more diverse studies are needed to fully understand who may benefit most from creatine supplementation in the context of depression.